Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentration versus time-kill curves

被引:19
作者
Schmidt, Stephan [1 ]
Schuck, Edgar [1 ]
Kumar, Vipul [1 ]
Burkhardt, Olaf [1 ,2 ]
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Hannover Med Sch, Dept Pulm Med, D-3000 Hannover, Germany
关键词
EC50; MIC; PK/PD modeling; time-kill curves;
D O I
10.1517/17460441.2.6.849
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selection of appropriate doses and dosing regimens is extremely important in antimicrobial therapy in order to increase the chances of clinical success and decrease the likelihood of toxic side effects and the development of resistance. Therefore, empirical treatment of bacterial infections is not reliable enough and more rational approaches are needed. Pharmacokinetic/pharmacodynamic (PK/PD) modeling provides a powerful tool to systematically link PK and PD properties in order to predict antimicrobial efficacy. However, commonly used minimum inhibitory concentration (MIC) based PK/PD indices, although easy to obtain, have a number of limitations. Thus, more reliable PK/PD indices need to be developed. The following article provides an overview of the present PK/PD approaches used in anti-infective therapy and discusses their role in improving drug therapy.
引用
收藏
页码:849 / 860
页数:12
相关论文
共 104 条
[11]  
Cawello W, 1997, INT J CLIN PHARM TH, V35, P414
[12]   Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance [J].
Cazzola, M ;
Matera, MG ;
Noschese, P .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2000, 13 (06) :249-256
[13]   Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data [J].
Christensen, Hege ;
Baker, Mark ;
Tucker, Geoffrey T. ;
Rostami-Hodjegan, Amin .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (12) :2778-2787
[14]  
Chulavatnatol Suvatna, 2003, Journal of the Medical Association of Thailand, V86, P781
[15]   Biomarkers in drug discovery and development: From target identification through drug marketing [J].
Colburn, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04) :329-341
[16]  
Craig W, 2001, RESP MED, V95, pS28
[17]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[18]   Does the dose matter? [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S233-S237
[19]   Re-evaluating current antibiotic therapy [J].
Craig, WA .
RESPIRATORY MEDICINE, 2001, 95 :S14-S21
[20]   Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy [J].
Dagan, R ;
Klugman, KP ;
Craig, WA ;
Baquero, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :129-140